Opinion|Videos|March 24, 2025
Practical Considerations for Therapies Considered by the Patient and Caregivers in RRMM
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how patients and caregivers considering late-line multiple myeloma therapies must navigate practical considerations including lengthy hospital stays for CAR-T cell therapy (typically two to four weeks), insurance approval challenges, travel to specialized treatment centers, the potential need for caregivers to take extended leave from work, management of posttreatment monitoring requirements, eligibility criteria related to organ function and performance status and planning for potential complications such as cytokine release syndrome or neurological toxicities that might require urgent care access.
Advertisement
Video content above is prompted by the following:
- What practical considerations should patients and caregivers be aware of when considering these therapies (e.g., hospital stays, eligibility, timing)?
Advertisement
Related to this article
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.
After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.
Relatives of people with BRCA1 or BRCA2 variants completed genetic testing more often when a navigator reached out directly than when they received a letter.
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.
A study of more than 17,000 patients ages 23 to 64, presented at ASTRO 2026, found that only about 28% took endocrine therapy consistently for five years, and people who skipped radiation were more likely to fall off. Here's what to weigh before making that choice.
Advertisement
Advertisement
Trending on CURE
1
Radiation Oncologist Answers Top Questions About Radiation Therapy
2
5 Years of Breast Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
3
Former Hospital Executive on Risks Patients With Cancer Face After Discharge
4
What Patients Should Know About Nipple-Sparing Mastectomy for Breast Cancer
5